Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review

J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell'Acqua, F. Kraja, A. Błażyńska-Spychalska, A. J. Łachiński, A. Surgo, R. Glynne-Jones, B. A. Jereczek-Fossa

Research output: Contribution to journalReview articlepeer-review


Background: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. Materials and methods: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. Results: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5–262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3–262.5 Gy. Conclusions: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.

Original languageEnglish
Pages (from-to)91-101
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Sep 1 2018


  • Colon cancer
  • Colorectal cancer
  • Oligometastases
  • Rectal cancer
  • SABR
  • SBRT
  • Stereotactic

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review'. Together they form a unique fingerprint.

Cite this